PDA with TB-500
Pentadeca arginate with TB-500
Written by Aaron CuhaReviewed Sep 2026
Also known as: Pentadeca arginate TB-500 blend, PDA TB blend, BPC arginate with TB-500
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
This is the 2026 version of the Wolverine stack. PDA is the same 15 amino acid chain as BPC-157 with a different salt attached. It is sold as an upgrade. Search the medical database for pentadeca arginate and you get nothing. Not one paper. The other half is TB-500, which is a 7 amino acid piece of a 43 amino acid protein.
What people take it for
- Tendon and ligament injuries.
- Muscle strains.
- Healing after surgery.
- People who think PDA is a better version of BPC-157.
What the trials actually showed
Nothing has been published on PDA under that name. No animal study. No human study. No test of whether the new salt is more stable, which is the only reason to pay more for it. Every claim made for PDA is a claim borrowed from BPC-157. For BPC-157 itself, the FDA counted five human studies with fewer than 110 people. None used a shot under the skin. A 2025 review found 35 of its 36 studies were in animals. TB-500 has no human study by any route. The trials people quote for it were done on the full protein, which is not what is in the vial. Sellers do not agree on how much of each goes in a vial, so this page will not give you a per unit number. Use the milligrams printed on your own label.
What people report
Reports, not trial results
The good
- Less stinging at the shot site than plain BPC-157. This is the most consistent report and the one thing the salt change might explain.
- Tendon and joint pain easing over two to six weeks.
The bad
- People who have run both say they cannot tell the difference from plain BPC-157 with TB-500.
- Nobody has tested a vendor PDA vial to see what is in it.
- The two parts do not share a schedule. One gets run daily and one weekly.
- You cannot turn one part down.
Where these come from: Peptide forums, clinic write-ups and seller pages. The sting comparison is not blinded and the two products look different in the vial.
My bottom line
PDA is BPC-157 with a new name and a better story. The one thing that would make it worth more money is the only thing nobody has tested.
An opinion, not a finding. I am a coach, not a doctor.
Overview
The 2026 replacement for the Wolverine stack, pairing the arginate salt of the BPC-157 sequence with the fragment sold as TB-500. PubMed returns no publication at all for pentadeca arginate, so the blend borrows evidence twice over: from a peptide it is a salt of, and from a protein one component is only a fragment of. Vial sizes are not consistent across vendors.
Pentadeca arginate, PDA, is sold as an upgrade to BPC-157. The sequence is the same fifteen amino acids; the counterion is arginate rather than acetate, and the marketing claim is better stability. Search PubMed for pentadeca arginate and you get nothing. Not a thin literature, no literature: no pharmacokinetic study, no stability comparison against the acetate salt, no animal model, no human data. Every claim made for PDA is a claim made for BPC-157 with an assumption bolted on that the salt does not matter, or that it matters in the direction the seller prefers.
Paired with it is TB-500, which a doping control laboratory characterised by mass spectrometry as Ac-LKKTETQ, the acetylated 17 to 23 fragment of thymosin beta 4. The research that sells this half is research on the 43 amino acid parent protein. Seven amino acids of it are in the vial.
So this is a two-component product where one component has no literature under its own name and the other has a literature belonging to a different molecule. That is not a criticism of the idea of tissue repair peptides. It is a precise statement of where the evidence for this particular vial sits, which is somewhere else.
On vial size, vendors do not agree and no split is canonical. Ten plus ten is the most frequently listed, and some sell PDA-dominant vials. Because no size is standard, this page does not put numbers on the draw. What can be said without inventing anything is the structural fact: whatever the split, the amounts move together, and the two components are dosed on completely different schedules when run alone. People run the BPC-157 sequence in microgram amounts once or twice daily, because the systematic review puts its half-life under thirty minutes. People run TB-500 in milligram loading doses and then weekly. A fixed blend cannot honour both.
Mechanism of action
PDA is assumed to work through BPC-157's pathways because it is the same peptide sequence, and that assumption has never been tested for the arginate form. The BPC-157 literature describes angiogenesis, growth factor receptor expression and reduced inflammatory cytokines, almost entirely in rodents. The Ac-LKKTETQ fragment binds actin. What an arginate salt does to absorption, to stability in solution, or to the shelf life of a mixed vial is unpublished.
Human evidence
None for the blend, none for PDA under its own name, and none for the fragment in the other half.
- Pentadeca arginate: no publication indexed in PubMed under that name. No pharmacokinetics, no stability data, no animal study, no human study.
- The underlying BPC-157 sequence: five human studies counted by FDA totalling fewer than 110 subjects, two of them meeting abstracts, none longer than two weeks, none subcutaneous.
- A 2025 systematic review of that sequence included 36 studies of which 35 were preclinical.
- TB-500: no human study by any route. The material is a seven amino acid fragment; the human trials people cite belong to the full thymosin beta 4 protein.
What this does not tell you: There is no published basis for the central marketing claim that the arginate salt behaves differently from the acetate salt, in either direction. Nobody has run the comparison.
What it has been measured to do
What people using it report
Uncontrolled and self-selected, so it cannot show that anything works. It is still the best guide on this page to what people actually do with PDA with TB-500, what they expect, and what goes wrong. The full account, including the negative reports, is below.
Nothing indexed yet
The 3 citations on this page do not report a result for any of the 36 goals indexed here. Registry entries, pharmacokinetics, safety reporting and regulatory records are not outcome evidence, and most of what sits here is one of those.
Reading the research record
PDA is a useful case study in how this market generates new products without generating new evidence. When FDA action made BPC-157 harder to sell under its own name, the same sequence reappeared as a salt with a new name, carrying the old peptide's literature in the marketing copy and none of it in the regulatory file. The stability claim is the part to watch, because it is the only thing distinguishing the two products and it is also the only claim with no data at all behind it.
The pairing with TB-500 repeats the Wolverine problem exactly. The fragment is sold on the strength of thymosin beta 4 research, and thymosin beta 4 is a different molecule. The nine-patient eye drop study people cite for the parent protein used eye drops, in nine people, on a molecule not in this vial.
The evidence, charted
Fig. 1a · evidence scale
0people have taken this in any study cited here
0 participants · 0 human studies
What this page cites instead is 1 in vitro study and 2 reviews. None of it involved giving the compound to a person.
Counted from the citation list on this page. A figure is drawn here only when a human study is cited; an empty one is the finding, not a gap in the page.
Fig. 1b · evidence mix
None of the 3 citations here are human work.
- In vitro · cells, tissue or a dish133%
- Review · summarises other work267%
Counted from the citation list on this page, typed as this page types it. It understates any literature larger than the sources we cite, and a review counts once however many studies it covers.
Fig. 2 · evidence over time
Evidence spans 3 distinct years, 2012 to 2026, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Fig. 5 · molecular identity
- Modality
- Blend
- Molecular weight
- Not on file
- Half-life
- Stated in words, not a number
- Sequence length
- None on file
see the exact wording below
Half-life as stated on file: Not defined for the blend. Nothing has been published for the arginate salt, for the fragment, or for the mixture.
No amino acid sequence is on file for PDA with TB-500, which is expected: a blend is not built from residues.
Fig. 6 · what is in the vial
No mass split can be drawn for this blend
Sellers do not publish a consistent vial size for PDA with TB-500, so the share of each component is not knowable from the outside. Splitting the bar evenly would invent the number this page exists to question.
- Pentadeca arginateamount not stated
- TB-500amount not stated
Component list from the product labels we hold. Amounts are label mass, never a dose.
Key studies & citations
- Review2025
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
544 articles screened, 36 included, of which 35 were preclinical and one was clinical. That single clinical study was a retrospective series in which 7 of 12 patients reported relief beyond six months after intra-articular BPC-157 for unspecified chronic knee pain. The review puts the half-life at under 30 minutes.
HSS Journal - Review2026
FDA briefing document on BPC-157 for the July 2026 PCAC meeting
FDA staff counted five published human studies of BPC-157 totalling fewer than 110 subjects, two of them meeting abstracts only, none dosing longer than two weeks, and none giving the peptide by subcutaneous injection. Staff found no adequate human data and mislabelled products in the market.
FDA - In vitro2012
Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential
A doping control laboratory ran the TB-500 product through high performance liquid chromatography and high resolution mass spectrometry and identified the contents as Ac-LKKTETQ, the acetylated 17 to 23 fragment of thymosin beta 4. Seven amino acids, not the 43 amino acid protein the marketing names.
Drug Testing and Analysis
What users report
Self-reported experiences, not evidence. Nothing below was measured under controlled conditions, and reports like these cannot separate a real effect from placebo, from the training or diet change that accompanied it, or from what the product actually contained. They are here because knowing what people describe, including what goes wrong, is worth reading alongside the studies.
- Less injection site stinging than acetate BPC-157, which is the most consistent report and the one thing the arginate claim might plausibly explain.
- Tendon and joint pain improving over two to six weeks.
- No difference at all from plain BPC-157 with TB-500, reported by people who have run both.
- Uncertainty about what was in the vial, since no independent assay of vendor PDA has been published.
Sources: Peptide forums including r/peptides, clinic write-ups and vendor pages. Uncontrolled self-reports. The sting comparison in particular is unblinded and the two products look different in the vial.
Frequently asked questions
Is PDA better than BPC-157?
Nobody has tested that. PubMed returns no publication for pentadeca arginate, so there is no stability comparison, no pharmacokinetic comparison and no head to head. The sequence is the same fifteen amino acids.
Has this blend been studied?
No. There is no study of PDA with TB-500 in any species, and no registered trial.
What size vial is standard?
There is not one. Vendors sell different splits and no size is canonical, which is why this page does not print a per-unit figure. Work the arithmetic from the milligram breakdown on the label you actually have.
Is the TB-500 in this the same as thymosin beta 4?
No. A doping laboratory identified the product as a seven amino acid fragment of the 43 amino acid protein. The human trials cited for thymosin beta 4 studied the full protein.
Why not just buy them separately?
That is the version you can control. The two components are dosed on different schedules when run alone, one roughly daily and one roughly weekly, and a fixed blend forces one schedule on both.